- Home
- / TriSalus Life Sciences
TriSalus Life Sciences
Stock Price
$4
2024-10-29
Market Capitalization
$117.2 M
2024-10-29
Revenue
$18.5 M
FY, 2023
TriSalus Life Sciences Summary
Company Summary
- Overview
- TriSalus Life Sciences (formerly MedTech Acquisition and Surefire Medical) is a company that develops a transformative platform for treating liver and pancreatic tumors. Its pipeline integrates immunomodulation therapy with proprietary intravascular regional delivery.
- Type
- Public
- Status
- Active
- Founded
- 2009
- HQ
- Westminster, CO, US | view all locations
- Website
- https://trisaluslifesci.com/
- Cybersecurity rating
Table of Contents
Key People
Mary Szela, Chief Executive Officer, President and Director
Steven Katz, Chief Medical Officer and Chairman SAB
Kerry Hicks, Director
LocationsView all
3 locations detected
Westminster, CO HQ
United States
6272 W 91st Ave
Bannockburn, IL
United States
2275 Half Day Road, Ste. 160
Cranston, RI
United States
1000 Chapel View Blvd
TriSalus Life Sciences Financials
Summary Financials
- Revenue (Q3, 2024)
- $7.3M
- Gross profit (Q3, 2024)
- $6.3M
- Net income (Q3, 2024)
- ($2.4M)
- Cash (Q3, 2024)
- $11.3M
- EBIT (Q3, 2024)
- ($8.7M)
- Enterprise value
- $127.6M